Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HWK 016

Next Previous
Drug Profile

HWK 016

Alternative Names: HWK-016

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator WuXi Biologics
  • Developer Whitehawk Therapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ovarian cancer

Most Recent Events

  • 07 Apr 2025 Whitehawk Therapeutics plans a phase I trial for Ovarian cancer(Parenteral) by the end of 2025 (Whitehawk Therapeutics pipeline, April 2025)
  • 19 Mar 2025 Preclinical trials in Ovarian cancer in USA (Parenteral)
  • 19 Dec 2024 Whitehawk Therapeutics in-licenses HWK 016 from WuXi Biologics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top